Literature DB >> 7945999

The role of active metabolites in drug toxicity.

M Pirmohamed1, N R Kitteringham, B K Park.   

Abstract

Adverse drug reactions can be caused by the parent drug or a metabolite of that drug. The metabolite may be stable or chemically reactive, the resultant toxicity being either a direct extension of the pharmacology of the drug, or unrelated to the known pharmacology of the drug and dependent on the chemical properties of the compound. Many different organ systems may be affected, and there are several mechanisms involved in determining organ-specific, and sometimes cell-selective, toxicity. An imbalance between bioactivation of a drug to a toxic metabolite and its detoxification is of prime importance in determining individual susceptibility. Such an imbalance may be genetically determined or acquired and, furthermore, may be systemic or tissue-specific. Prevention of metabolite-mediated toxicity is possible once the mechanism of toxicity has been elucidated.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7945999     DOI: 10.2165/00002018-199411020-00006

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  257 in total

Review 1.  Bioactivation in chemical teratogenesis.

Authors:  M R Juchau
Journal:  Annu Rev Pharmacol Toxicol       Date:  1989       Impact factor: 13.820

2.  Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Authors:  R E Pounder; E R Craven; J S Henthorn; J M Bannatyne
Journal:  Gut       Date:  1975-03       Impact factor: 23.059

3.  Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity.

Authors:  B H Lauterburg; M E Velez
Journal:  Gut       Date:  1988-09       Impact factor: 23.059

4.  Valproic acid hepatic fatalities: a retrospective review.

Authors:  F E Dreifuss; N Santilli; D H Langer; K P Sweeney; K A Moline; K B Menander
Journal:  Neurology       Date:  1987-03       Impact factor: 9.910

5.  Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

Authors:  K Chiba; A Trevor; N Castagnoli
Journal:  Biochem Biophys Res Commun       Date:  1984-04-30       Impact factor: 3.575

6.  Renal impairment with chronic hydrocarbon exposure.

Authors:  M Yaqoob; G M Bell; A Stevenson; H Mason; D F Percy
Journal:  Q J Med       Date:  1993-03

7.  Enzymatic and non-enzymatic reduction of N-acetyl-p-benzoquinone imine and some properties of the N-acetyl-p-benzosemiquinone imine radical.

Authors:  G Powis; B A Svingen; D C Dahlin; S D Nelson
Journal:  Biochem Pharmacol       Date:  1984-08-01       Impact factor: 5.858

8.  Fatal liver failure in 16 children with valproate therapy.

Authors:  D Scheffner; S König; I Rauterberg-Ruland; W Kochen; W J Hofmann; S Unkelbach
Journal:  Epilepsia       Date:  1988 Sep-Oct       Impact factor: 5.864

9.  Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.

Authors:  D M Roden; S B Reele; S B Higgins; G R Wilkinson; R F Smith; J A Oates; R L Woosley
Journal:  Am J Cardiol       Date:  1980-09       Impact factor: 2.778

10.  Testosterone-mediated regulation of mouse renal cytochrome P-450 isoenzymes.

Authors:  C J Henderson; A R Scott; C S Yang; C R Wolf
Journal:  Biochem J       Date:  1990-03-15       Impact factor: 3.857

View more
  15 in total

Review 1.  Adverse drug reactions: back to the future.

Authors:  Munir Pirmohamed; B Kevin Park
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

Review 2.  Reactive metabolites and adverse drug reactions: clinical considerations.

Authors:  Sandra R Knowles; Lori E Shapiro; Neil H Shear
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

3.  What is drug safety?: celebrating 20 years of the Drug Safety journal.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

4.  Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).

Authors:  Christian Maass; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  Integr Biol (Camb)       Date:  2017-04-18       Impact factor: 2.192

5.  EIDOS: a mechanistic classification of adverse drug effects.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

Review 6.  Adverse drug reactions.

Authors:  M Pirmohamed; A M Breckenridge; N R Kitteringham; B K Park
Journal:  BMJ       Date:  1998-04-25

Review 7.  Overview of enzymes of drug metabolism.

Authors:  U A Meyer
Journal:  J Pharmacokinet Biopharm       Date:  1996-10

Review 8.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 9.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 10.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.